Emerging paradigms in targeted treatments for Asian patients with NSCLC
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.2015.1040391
Reference55 articles.
1. Global cancer statistics
2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
3. Protein kinase inhibitors to treat non-small-cell lung cancer
4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
5. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells;OncoTargets and Therapy;2023-11
2. PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model;International Immunopharmacology;2022-04
3. FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway;Frontiers in Pharmacology;2022-01-19
4. The role of brain metastases in patients with pulmonary adenocarcinoma: a retrospective study;Annals of Palliative Medicine;2021-12
5. SIRT6 through PI3K /Akt/ mTOR signaling pathway to enhance radiosensitivity of non‐Small cell lung cancer and inhibit tumor progression;IUBMB Life;2021-06-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3